Almirall: 2015 first-half growth driven by dermatology sales

Almirall announced that like-for-like net sales grew for the first half of 2015, which was driven by its dermatology franchise, according to a press release.

Net sales of 359.4 million euros ($397 million) were boosted by the dermatology franchise growth of 35.2% (year over year), the release said. The dermatology therapeutic area accounted for 41% of total net sales compared with 31% in a like-for-like basis compared to the same time in 2014, the release reported.

Almirall reported total revenues of 407.9 million euros, on a like-for-like basis, which excluded sales of Eklira (aclidinium bromide), and total revenue of 370.4 million euros, which represented an increase of 5.3%, according to the release

“Dermatology continues to be the key growth driver, led in particular by Acticlate [doxycycline; for severe acne] in the U.S. with a notable performance also from our European actinic keratosis franchise,” Eduardo Sanchiz, CEO of the Barcelona, Spain-based company, said in the release. “Our number one priority now is continuing to building on dermatology via [mergers and acquisitions, research and development] and in-licensing in order to generate sustainable shareholder value.”

Reference: www.almirall.com